Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy

Digestive Diseases and Sciences

Volumn 62, Issue 9, 2017, Pages 2569-2577

  de Lédinghen, Victor ^a,b   Hiriart, Jean Baptiste ^a   Vergniol, Julien ^a   Merrouche, Wassil ^a   Bedossa, Pierre ^c   Paradis, Valérie ^c  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BEAUJON HOSPITAL   (France)

Author keywords

Controlled attenuation parameter (CAP); Fibroscan; Liver stiffness; Metabolic syndrome; NAFLD; Obesity; Steatosis; Transient elastography

Indexed keywords

ALBUMIN; ALCOHOL; ALKALINE PHOSPHATASE; TRIACYLGLYCEROL;

ADULT; ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED ATTENUATION PARAMETER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELASTOGRAPH; FATTY LIVER; FEMALE; HEPATOBILIARY PARAMETERS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; BIOPSY; CLINICAL TRIAL; COMPARATIVE STUDY; DEVICES; DIAGNOSTIC IMAGING; ECHOGRAPHY; END STAGE LIVER DISEASE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STANDARDS;

ADULT; AGED; AREA UNDER CURVE; BIOPSY; END STAGE LIVER DISEASE; FEMALE; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY;

EID: 85020065411     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-017-4638-3     Document Type: Article

References (22)

1. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131.
2. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.
3. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–1835.
4. Chon YE, Jung KS, Kim SU, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int. 2014;34:102–109.
5. de Ledinghen V, Vergniol J, Capdepont M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014;60:1026–1031.
6. de Ledinghen V, Wong GL, Vergniol J, et al. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016;31:848–855.
7. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022–1030. doi:10.1016/j.jhep.2016.12.022.
8. Mi YQ, Shi QY, Xu L, et al. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan(R): validation in chronic hepatitis B. Dig Dis Sci. 2015;60:243–251.
9. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol. 2012;36:13–20.
10. Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012;107:1862–1871.
11. Sasso M, Audiere S, Kemgang A, et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the Fibroscan: a pilot study assessing diagnostic accuracy. Ultrasound Med Biol. 2016;42:92–103.
12. de Ledinghen V, Vergniol J. Transient elastography (Fibroscan). Gastroenterol Clin Biol. 2008;32:58–67.
13. Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–1759.
14. Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med. 2000;45:23–41.
15. Team. RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2015. https://www.R-project.org/.
16. Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2014;29:1470–1476.
17. Myers RP, Pollett A, Kirsch R, et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–910.
18. WHO. Obesity and overweight—fact sheet n°311. http://www.who.int/mediacentre/factsheets/fs311/en/: WHO; 2015.
19. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10:837–858.
20. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682–1698.
21. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, american college of gastroenterology, and the American gastroenterological association. Hepatology. 2012;55:2005–2023.
22. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai study. Am J Gastroenterol. 2013;108:1299–1304.